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The inability to catabolize glycosaminoglycans successfully results in the storage of this undegraded material in the lysosomes. This causes a chronic and progressive condition, known as mucopolysaccharidosis, characterized by a variety of physiological problems often leading to organ failure and premature death. 1 Mucopolysaccharidosis type VII (MPS VII), or Sly syndrome, is the lysosomal storage disease that occurs when there is insufficient ␤-glucuronidase (GUS); it is characterized by mental retardation, abnormal skeletal development, distorted features and organ malfunctions. 2 A mouse model for this disease has provided an experimental paradigm for the study of gene therapy approaches to this and similar genetic deficiencies. 3 Of several approaches that have been tested, one of the most promising has been the use of adeno-associated virus (AAV) vectors to deliver the GUS gene to mutant mice via a single intravenous injection. 4 However, this treatment did not result in GUS enzyme in the brain, an organ that has proved to be particularly resistant to most forms of gene therapy. 5, 6 Direct administration of therapeutic agents to the brain or brain ventricles is intrinsically difficult and risky and generally provides only highly localized benefit. 5, 7 Here we report the administration of a recombinant viral vector, AAV-GUS, via intrathecal injection into the cerebrospinal fluid. This route of administration is relatively benign and results in significant GUS enzyme activity in the brain. Intrathecal treatment of either newborn or adult mutant mice results in long-term elimination of storage granules in brain tissue.
AAV-GUS contains a murine GUS cDNA driven by a All mice received a total of 10 12 AAV-GUS particles within the first 3 days postpartum. Data from two mice treated for 17 weeks were averaged with data from one mouse treated for 22 weeks. Similarly, data from one mouse at 37 weeks and two mice at 39 weeks were combined. Data are means ± s.e. MPS mice, which carry a naturally occurring mutation in the GUS gene, 3, 11 were bred and maintained as described elsewhere. 4 AAV-GUS has been described 4 and was prepared using a virusfree, vector packaging system 12 generously provided by Avigen Inc (Alameda, CA, USA). Intravenous injection into neonates was via the superficial temporal vein and consisted of vector suspended in 100 l saline. The injection mixture also contained 2% non-toxic dye (Schilling green food coloring), which allowed us to monitor the success of the injection procedure. GUS enzyme was assayed using 4-methylumbelleriferyl-␤-glucuronide as the substrate. 13 One unit is the amount of enzyme forming 1 mol of product per hour at 37°C and specific activity is in units per gram (wet weight) of tissue.
CMV promoter. Previous results showed that intramuscular administration of this vector to adult MPS mice resulted in sustained, high expression of GUS confined to the site of injection. Intravenous administration of AAV-GUS resulted in lower, but more widely distributed Tables 1 and  2 ) and vector DNA. expression of GUS. This was accompanied by the successful elimination of storage material in liver, but not brain. 4 The amount of GUS activity required to eliminate the MPS VII phenotype in mice is estimated to be only 1-3% of the normal, non-mutant activity in each tissue. 4 Enzyme replacement studies using intravenous injection of GUS enzyme into MPS mice showed that the brains of neonatal mice were more accessible to the therapeutic protein than the brains of adult mice. 8, 9 Although this enzyme replacement therapy provided only a temporary source of therapeutic protein, the health and development of mice treated as newborns was markedly improved.
9 Therefore, we injected newborn MPS VII mice intravenously with AAV-GUS (10 12 particles per mouse), killed mice after 17 to 39 weeks and measured GUS activity in several tissues (Table 1) . Enzyme activity was elevated most dramatically in liver and heart and only marginally in kidney and brain. This tissue distribution of GUS activity was similar to that seen in adult MPS mice treated by intravenous injection of the vector. 4 As in the previously reported treatment of adult mice, storage granules in livers of mice treated as newborns were completely eliminated (data not shown). In brain, storage granules were not completely eliminated, but were reduced in size and number after treatment of newborns (Figure 1d ). This partial reduction of stored material in brain was a distinct improvement compared with mice treated as adults (Figure 1c) . Apparently even the very low levels of GUS in the brain resulting from intravenous treatment of newborns were sufficient for partial improvement.
Using an AAV vector carrying the green fluorescent protein gene, Peel et al 10 showed expression of the reporter gene in spinal cord following intrathecal administration in adult rats. Therefore, to improve delivery of AAV-GUS to the brain, we administered the vector by intrathecal injection into neonatal MPS mice. At increasing times after this treatment mice were killed and tissues were analyzed. Therapeutic levels of GUS enzyme were observed in brain for every animal treated (Table 2) . Relatively large animal to animal variation in GUS may have obscured any trend for expression levels to change over the 13-week time scale, but it is clear that the kinetics of expression in brain do not follow the prolonged, greater than 1000-fold increase observed when this same vector was injected into muscle. 4 GUS activity in spinal cord, 
Neonatal mice were 3 days old when given 1.5 × 10 11 particles of vector. Adult mice were 7-13 weeks old at the time of injection and received 5 × 10 11 particles. GUS activity in spinal cord was not measured in younger animals. For intrathecal administration to newborns, mice were anesthetized by inhalation of halothane, and vector in 30 l saline (with 2% dye) was injected between the sixth lumbar and second sacral vertebrae using a 30-gauge needle. Successful introduction into the cerebrospinal fluid space could be detected immediately as a green streak extending from the spinal column and diffusing into the brain. For intrathecal administration to adults, MPS mice were anesthetized with avertin (tribromoethanol) and a 1-cm incision was made through the skin parallel to the spine to make the positions of individual vertebrae visible. Vector in 100 l saline (with 2% dye) was injected between the last thoracic and second lumbar vertebrae. Data are means ± s.e. ND, not determined.
the actual site of vector injection, was particularly high and variable, whereas GUS levels in liver, heart and muscle were modest. These low but significant levels were probably due to vector that entered the circulatory system rather than being confined to the cerebrospinal fluid. Enzyme activities in lung, kidney and spleen were uniformly low, less than 1% of normal and are not shown. Histopathology indicated that brain tissue from these treated mice was completely free of storage vacuoles (Figure 1f) .
Although early treatment is clearly desirable, MPS diseases in humans are not usually detected until some damage has already appeared and lysosomal storage is already significant. Thus, we tested whether we could successfully treat adult MPS mice in which storage granules had already developed and in which the brain had already been shown to be less accessible to AAV-GUS introduced intravenously. Intrathecal administration of AAV-GUS to adult MPS mice did result in significant GUS enzyme activity in the brain (Table 2 , last line). This was accompanied by the elimination of storage vacuoles in the brain (Figure 1e ), suggesting that previous constraints to successful treatment had been overcome.
Brain samples from mice treated as adults were also tested for the presence of vector DNA using a quantitative PCR method. 4 Vector DNA levels were 0.65 ± 0.23 pg vector DNA per g total (genomic) DNA at 6 weeks after treatment by intrathecal injection. This was equivalent to an average of about 0.8 copies of the vector per diploid nucleus, suggesting that some, but not all, brain cells had the capacity to make GUS. This implies that some brain cells benefit from a bystander effect, which is consistent with observations that GUS can be transferred between cells that are in close proximity in the brain. 5 Although each MPS mouse treated by intrathecal administration of AAV-GUS showed no lysosomal storage in the brain, the extent of GUS expression in brain varied substantially from mouse to mouse. This was probably due to variation in the injection process, where the target space was very small and the volume administered was relatively large. Administration to larger organisms should be technically easier and more consistent. The results presented suggest that this type of treatment might eventually be useful for providing relief from the mental deterioration that accompanies many of the lysosomal storage diseases in humans.
